Indian origin pharmaceutical giant Zydus Lifesciences Limited has announced that it has received marketing authorisation from the National Medical Products Administration (NMPA), China, for its Venlafaxine Extended-Release (ER) Capsules, available in 75 mg and 150 mg strengths.

This marks Zydus’ first-ever approval from the NMPA, reinforcing the company’s strategic commitment to strengthening its presence in international markets and expanding its portfolio across regulated territories.

Venlafaxine ER Capsules are indicated for the treatment of Major Depressive Disorder (MDD), Generalised Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD). The formulation works by restoring the balance of serotonin and norepinephrine—key neurotransmitters that influence mood and emotional stability—thereby helping to alleviate symptoms of depression and anxiety.

The approved product will be manufactured at Zydus’ state-of-the-art facility in Moraiya, Ahmedabad, which adheres to global regulatory and quality standards.

This regulatory nod from China’s NMPA not only enhances Zydus’ global footprint but also underscores India’s growing role as a reliable hub for high-quality, affordable pharmaceuticals. The approval opens up new opportunities for the company to serve patients in one of the world’s largest and fastest-growing healthcare markets.

Also read: Servier India Partners with MedGenome & Strand Life Sciences, Expanding AML & CCA Testing

With this development, Zydus continues to advance its mission of delivering accessible, science-driven therapies that improve quality of life across therapeutic areas and geographies.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!